|
US319A
(en)
|
|
1837-07-31 |
|
Improvement in machines for breaking and dressing hemp and flax |
|
US8236A
(en)
|
|
1851-07-22 |
|
Hanging cakriage-body |
|
US4434150A
(en)
|
1981-10-19 |
1984-02-28 |
Ortho Diagnostic Systems, Inc. |
Immunological reagents employing polymeric backbone possessing reactive functional groups
|
|
US4486414A
(en)
|
1983-03-21 |
1984-12-04 |
Arizona Board Of Reagents |
Dolastatins A and B cell growth inhibitory substances
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US4936824A
(en)
|
1987-05-15 |
1990-06-26 |
The Boc Group, Inc. |
Infant incubator with air curtain
|
|
US4880078A
(en)
|
1987-06-29 |
1989-11-14 |
Honda Giken Kogyo Kabushiki Kaisha |
Exhaust muffler
|
|
US4816444A
(en)
|
1987-07-10 |
1989-03-28 |
Arizona Board Of Regents, Arizona State University |
Cell growth inhibitory substance
|
|
IL89220A
(en)
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
|
|
US5076973A
(en)
|
1988-10-24 |
1991-12-31 |
Arizona Board Of Regents |
Synthesis of dolastatin 3
|
|
FI903489A7
(fi)
|
1988-11-11 |
1990-07-10 |
Medical Res Council |
Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
|
|
US4978744A
(en)
|
1989-01-27 |
1990-12-18 |
Arizona Board Of Regents |
Synthesis of dolastatin 10
|
|
JPH0684824B2
(ja)
|
1989-05-15 |
1994-10-26 |
清水建設株式会社 |
香り供給方法および香り供給装置
|
|
US4879278A
(en)
|
1989-05-16 |
1989-11-07 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
|
|
US4986988A
(en)
|
1989-05-18 |
1991-01-22 |
Arizona Board Of Regents |
Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5138036A
(en)
|
1989-11-13 |
1992-08-11 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14
|
|
US5124471A
(en)
|
1990-03-26 |
1992-06-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Bifunctional dtpa-type ligand
|
|
JPH06507404A
(ja)
|
1991-05-01 |
1994-08-25 |
ヘンリー エム．ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン |
感染性の呼吸性疾患の治療方法
|
|
US6287792B1
(en)
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
ZA932522B
(en)
|
1992-04-10 |
1993-12-20 |
Res Dev Foundation |
Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US6034065A
(en)
|
1992-12-03 |
2000-03-07 |
Arizona Board Of Regents |
Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
|
|
US5410024A
(en)
|
1993-01-21 |
1995-04-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
WO1994016729A1
(en)
|
1993-01-28 |
1994-08-04 |
Neorx Corporation |
Targeted nitric oxide pathway or nitric oxide synthase modulation
|
|
US5934272A
(en)
|
1993-01-29 |
1999-08-10 |
Aradigm Corporation |
Device and method of creating aerosolized mist of respiratory drug
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
WO1995015770A1
(en)
|
1993-12-09 |
1995-06-15 |
Neorx Corporation |
Pretargeting methods and compounds
|
|
US5530097A
(en)
|
1994-08-01 |
1996-06-25 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory peptide amides
|
|
US5521284A
(en)
|
1994-08-01 |
1996-05-28 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide amides and esters
|
|
US5504191A
(en)
|
1994-08-01 |
1996-04-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide methyl esters
|
|
US5554725A
(en)
|
1994-09-14 |
1996-09-10 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Synthesis of dolastatin 15
|
|
US5599902A
(en)
|
1994-11-10 |
1997-02-04 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Cancer inhibitory peptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
|
EP0871490B1
(en)
|
1995-12-22 |
2003-03-19 |
Bristol-Myers Squibb Company |
Branched hydrazone linkers
|
|
IT1282692B1
(it)
|
1996-02-27 |
1998-03-31 |
San Raffaele Centro Fond |
Citochine modificate per l'uso in terapia
|
|
US5985320A
(en)
|
1996-03-04 |
1999-11-16 |
The Penn State Research Foundation |
Materials and methods for enhancing cellular internalization
|
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
|
US5985309A
(en)
|
1996-05-24 |
1999-11-16 |
Massachusetts Institute Of Technology |
Preparation of particles for inhalation
|
|
US5855913A
(en)
|
1997-01-16 |
1999-01-05 |
Massachusetts Instite Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
|
DE69732306T2
(de)
|
1997-01-16 |
2006-01-12 |
Massachusetts Institute Of Technology, Cambridge |
Zubereitung von partikelhaltigen arzneimitteln zur inhalation
|
|
NZ336924A
(en)
|
1997-02-13 |
2001-06-29 |
Bone Care Int Inc |
Targeted therapeutic delivery of vitamin D compounds via a Vitamin D conjugate
|
|
CA2282504A1
(en)
|
1997-02-25 |
1998-08-27 |
Jun-Ping Xu |
Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
|
|
JPH11154024A
(ja)
|
1997-09-16 |
1999-06-08 |
Sumitomo Electric Ind Ltd |
負荷液圧の制御方法
|
|
WO1999019500A1
(en)
|
1997-10-10 |
1999-04-22 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Healt H And Human Services |
Complex of biotinylated viral vector and ligand for targeted gene delivery
|
|
US6280955B1
(en)
|
1997-12-16 |
2001-08-28 |
Tularik Inc. |
Interleukin-1 receptor accessory proteins, nucleic acids and methods
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
ES2198922T3
(es)
|
1998-06-24 |
2004-02-01 |
Advanced Inhalation Research, Inc. |
Particulas porosas grandes emitadas por un inhalador.
|
|
EP2275540B1
(en)
|
1999-04-09 |
2016-03-23 |
Kyowa Hakko Kirin Co., Ltd. |
Method for controlling the activity of immunologically functional molecule
|
|
CN1269087C
(zh)
|
1999-07-31 |
2006-08-09 |
朴奎珍 |
使用数字音频和字幕数据的学习方法和装置
|
|
US6323315B1
(en)
|
1999-09-10 |
2001-11-27 |
Basf Aktiengesellschaft |
Dolastatin peptides
|
|
WO2001090198A1
(en)
|
2000-05-24 |
2001-11-29 |
Ludwig Institute For Cancer Research |
Multicomponent conjugates which bind to target molecules and stimulate cell lysis
|
|
US7449308B2
(en)
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
|
US7029872B2
(en)
|
2000-06-28 |
2006-04-18 |
Glycofi, Inc |
Methods for producing modified glycoproteins
|
|
AU2013203432A1
(en)
|
2000-06-29 |
2013-05-02 |
Abbvie Inc. |
Dual specificity antibodies and methods of making and using
|
|
US20030026806A1
(en)
|
2000-10-27 |
2003-02-06 |
Amgen Inc. |
Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
|
|
US20030083263A1
(en)
|
2001-04-30 |
2003-05-01 |
Svetlana Doronina |
Pentapeptide compounds and uses related thereto
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US20030138803A1
(en)
|
2001-07-27 |
2003-07-24 |
Brooksbank Robert Alan |
Identification and use of molecules implicated in pain
|
|
US20030049255A1
(en)
|
2001-08-07 |
2003-03-13 |
Sims John E. |
Interleukin-1 receptors in the treatment of diseases
|
|
WO2003016466A2
(en)
|
2001-08-17 |
2003-02-27 |
Eli Lilly And Company |
ANTI-Aβ ANTIBODIES
|
|
PL213948B1
(pl)
|
2001-10-25 |
2013-05-31 |
Genentech Inc |
Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
|
|
JP2005538049A
(ja)
|
2002-05-01 |
2005-12-15 |
トレリス バイオサイエンス、インク． |
２元的ないし多元的ターゲティング及びその使用
|
|
ES2369542T3
(es)
|
2002-07-31 |
2011-12-01 |
Seattle Genetics, Inc. |
Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
|
|
EP1542723B1
(en)
|
2002-08-16 |
2011-02-23 |
ImmunoGen, Inc. |
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
|
|
MXPA05002514A
(es)
|
2002-09-06 |
2005-05-27 |
Amgen Inc |
Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
|
|
US7388079B2
(en)
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
AR045614A1
(es)
|
2003-09-10 |
2005-11-02 |
Hoffmann La Roche |
Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
|
|
US20050129685A1
(en)
|
2003-09-18 |
2005-06-16 |
Jingtai Cao |
Use of IL-1 blockers to prevent corneal inflammation and neovascularization
|
|
ES2605443T3
(es)
|
2003-11-06 |
2017-03-14 |
Seattle Genetics, Inc. |
Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
|
|
EP2392586A1
(en)
|
2004-02-20 |
2011-12-07 |
The Trustees of The University of Pennsylvania |
Binding peptidomimetics and uses of the same
|
|
US20050226882A1
(en)
|
2004-04-08 |
2005-10-13 |
Awdalla Essam T |
Method and multicomponent conjugates for treating cancer
|
|
JP2007535317A
(ja)
|
2004-04-15 |
2007-12-06 |
グライコフィ， インコーポレイテッド |
下等真核生物におけるガラクトシル化された糖タンパク質の産生
|
|
EP1751175B1
(en)
|
2004-05-05 |
2012-07-25 |
VALORISATION-RECHERCHE, Société en Commandite |
Interleukin-1 receptor antagonists, compositions, and methods of treatment
|
|
US8618054B2
(en)
|
2004-05-05 |
2013-12-31 |
Valorisation-Rechereche Société en Commandite |
Interleukin-1 receptor antagonists, compositions, and methods of treatment
|
|
US7691962B2
(en)
|
2004-05-19 |
2010-04-06 |
Medarex, Inc. |
Chemical linkers and conjugates thereof
|
|
NZ551180A
(en)
|
2004-06-01 |
2009-10-30 |
Genentech Inc |
Antibody drug conjugates and methods
|
|
GB0419124D0
(en)
|
2004-08-27 |
2004-09-29 |
Proteome Sciences Plc |
Methods and compositions relating to Alzheimer's disease
|
|
EP1695717A1
(en)
|
2005-02-23 |
2006-08-30 |
Ludwig-Maximilians-Universität |
Transport of nano-and macromolecular structures into cytoplasm and nucleus of cells
|
|
AU2014203217B2
(en)
|
2005-08-19 |
2017-03-30 |
Abbvie Inc. |
Dual variable domain immunoglobin and uses thereof
|
|
US20070248597A1
(en)
|
2005-10-21 |
2007-10-25 |
Henley Charles M Iii |
Methods of decreasing vascular calcification using IL-1 inhibitors
|
|
WO2007096398A1
(en)
|
2006-02-22 |
2007-08-30 |
University Of Zurich |
Soluble receptors and methods for treating autoimmune or demyelinating diseases
|
|
WO2007150020A1
(en)
|
2006-06-23 |
2007-12-27 |
Simon Paul M |
Targeted immune conjugates
|
|
US7560530B1
(en)
|
2006-07-20 |
2009-07-14 |
Schering Corporation |
IL-33 receptor
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US7767206B2
(en)
|
2006-10-02 |
2010-08-03 |
Amgen Inc. |
Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
|
|
US7632490B2
(en)
|
2006-10-20 |
2009-12-15 |
Regeneron Pharmaceuticals, Inc. |
Use of IL-1 antagonists to treat gout
|
|
US7598028B2
(en)
|
2006-11-28 |
2009-10-06 |
The Regents Of The University Of Michigan |
Compositions and methods for detecting and treating prostate disorders
|
|
WO2008086064A2
(en)
|
2007-01-03 |
2008-07-17 |
The Regents Of The University Of California |
An apparatus and method for in vivo intracellular transfection of gene, sirna, shrna vectors, and other biomedical diagnostic and therapeutic drugs and molecules for the treatment of arthritis and other orthopedic diseaseas in large animals and humans
|
|
US8057798B2
(en)
|
2007-02-02 |
2011-11-15 |
Baylor Research Institute |
Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells
|
|
TWI422594B
(zh)
|
2007-02-02 |
2014-01-11 |
Baylor Res Inst |
經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
|
|
NZ579644A
(en)
|
2007-02-16 |
2012-05-25 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
CA2717656A1
(en)
|
2007-02-23 |
2008-08-28 |
Baylor Research Institute |
Activation of human antigen-presenting cells through clec-6
|
|
EP2132226B1
(en)
|
2007-02-23 |
2019-03-27 |
Baylor Research Institute |
Activation of human antigen-presenting cells through dendritic cell lectin-like oxidized ldl receptor-1 (lox-1)
|
|
EP2208737B1
(en)
|
2007-05-03 |
2017-07-05 |
Lysomab GmbH |
Complement factor H-derived short consensus repeat-antibody constructs
|
|
EP2187900B1
(en)
|
2007-08-16 |
2016-11-09 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
|
|
WO2009120905A2
(en)
|
2008-03-26 |
2009-10-01 |
Cellerant Therapeutics, Inc. |
Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
|
|
CN101348526B
(zh)
|
2008-08-29 |
2011-08-17 |
浙江大学 |
一种抗白细胞介素-8抗体
|
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
|
EP2385839B1
(en)
|
2009-01-09 |
2014-11-26 |
The Schepens Eye Research Institute, Inc. |
Therapeutic compositions for treatment of corneal disorders
|
|
JP2012516445A
(ja)
|
2009-01-27 |
2012-07-19 |
ホロジック，インコーポレイテッド |
体液における新生児敗血症の検出のためのバイオマーカー
|
|
US8444983B2
(en)
|
2009-03-23 |
2013-05-21 |
Quark Pharmaceuticals, Inc. |
Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
|
|
JP2012525154A
(ja)
|
2009-05-01 |
2012-10-22 |
オレゴン ヘルス アンド サイエンス ユニバーシティ |
生体内でヒト肝細胞を増大させる方法
|
|
DE102009026075A1
(de)
|
2009-06-30 |
2011-01-05 |
Röhm Gmbh |
Bohrvorrichtung
|
|
WO2011017294A1
(en)
|
2009-08-07 |
2011-02-10 |
Schering Corporation |
Human anti-rankl antibodies
|
|
GB2472856B
(en)
|
2009-08-21 |
2012-07-11 |
Cantargia Ab |
IL1-RAP modulators and uses thereof
|
|
EP2475388B1
(en)
|
2009-09-10 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Use of il-33 antagonists to treat fibrotic disease
|
|
CN102712696A
(zh)
|
2009-09-16 |
2012-10-03 |
弗·哈夫曼-拉罗切有限公司 |
包含卷曲螺旋和/或系链的蛋白质复合体及其用途
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
US9149544B2
(en)
|
2009-11-06 |
2015-10-06 |
The Penn State Research Foundation |
Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
|
|
GB0919751D0
(en)
|
2009-11-11 |
2009-12-30 |
King S College Hospital Nhs Fo |
Conjugate molecule
|
|
WO2011163452A2
(en)
|
2010-06-24 |
2011-12-29 |
Eleven Biotherapeutics, Inc. |
Treating surface of the eye disorders
|
|
WO2012027494A1
(en)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Bispecific targeting reagents
|
|
US20120201746A1
(en)
|
2010-12-22 |
2012-08-09 |
Abbott Laboratories |
Half immunoglobulin binding proteins and uses thereof
|
|
US20120195900A1
(en)
|
2010-12-22 |
2012-08-02 |
Abbott Laboratories |
Tri-variable domain binding proteins and uses thereof
|
|
JP5940093B2
(ja)
|
2011-01-19 |
2016-06-29 |
カンタージア アクチエボラーグ |
抗ｉｌ−１ｒａｐ抗体及びヒトを処置するためのそれらの使用
|
|
WO2012122228A2
(en)
|
2011-03-07 |
2012-09-13 |
Temple University - Of The Commonwealth System Of Higher Education |
Biomarkers of chronic obstructive pulmonary disease
|
|
WO2012142391A1
(en)
|
2011-04-15 |
2012-10-18 |
Merck Patemt Gmbh |
Anti- il-1r1 inhibitors for use in cancer
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
JP2014527398A
(ja)
|
2011-06-21 |
2014-10-16 |
オンコファクター コーポレイション |
がんの療法および診断のための組成物および方法
|
|
US9873918B2
(en)
|
2011-08-11 |
2018-01-23 |
Albert Einstein College Of Medicine, Inc. |
Treatment of acute myeloid leukemia and myelodysplastic syndromes
|
|
US9534058B2
(en)
|
2012-02-08 |
2017-01-03 |
Abbvie Stemcentrx Llc |
Anti-CD324 monoclonal antibodies and uses thereof
|
|
US20130303509A1
(en)
|
2012-05-11 |
2013-11-14 |
Abbvie Inc. |
Nampt inhibitors
|
|
US20150315279A1
(en)
|
2012-12-21 |
2015-11-05 |
Cellerant Therapeutics, Inc. |
Antibodies that bind membrane-bound il1rap
|
|
WO2014135655A1
(en)
|
2013-03-06 |
2014-09-12 |
Institut Curie |
Compositions and methods for treating muscle-invasive bladder cancer
|
|
KR101813708B1
(ko)
|
2013-03-13 |
2017-12-29 |
(주) 아이벤트러스 |
소수성 상호작용 부위내에 전기적 상호작용이 도입된 단백질 및 이의 제조방법
|
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
|
WO2014144292A2
(en)
|
2013-03-15 |
2014-09-18 |
Sanofi Pasteur Biologics , Llc |
Antibodies against clostridium difficile toxins and methods of using the same
|
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
|
JP6404314B2
(ja)
|
2013-03-15 |
2018-10-10 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｉｌ−３３拮抗薬とその使用法
|
|
CA2911547A1
(en)
|
2013-05-31 |
2014-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methods of using il-1 antagonists to treat alzheimer's disease
|
|
CA2918518C
(en)
|
2013-07-19 |
2022-08-16 |
Universiteit Gent |
Targeted modified il-1 family members
|
|
GB201403875D0
(en)
|
2014-03-05 |
2014-04-16 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
NO2785538T3
(enExample)
|
2014-05-07 |
2018-08-04 |
|
|
|
WO2016004389A2
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Monovalent binding proteins
|
|
GB201413913D0
(en)
|
2014-08-06 |
2014-09-17 |
Cantargia Ab |
Novel antibodies and uses thereof
|
|
US10261098B2
(en)
|
2014-08-18 |
2019-04-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Biomarkers for diagnosis and management of neuro-immunological diseases
|
|
JP2016044126A
(ja)
|
2014-08-19 |
2016-04-04 |
国立大学法人埼玉大学 |
次世代型フラグメント抗体作製用ｄｎａライブラリの作製方法、その方法を用いて作製されたライブラリ、及び次世代型フラグメント抗体
|
|
JP6929771B2
(ja)
|
2014-11-10 |
2021-09-01 |
ジェネンテック， インコーポレイテッド |
抗インターロイキン−３３抗体及びその使用
|
|
US11708608B2
(en)
|
2014-11-10 |
2023-07-25 |
Genentech, Inc. |
Therapeutic and diagnostic methods for IL-33-mediated disorders
|
|
SG11201702550WA
(en)
|
2014-11-10 |
2017-04-27 |
Hoffmann La Roche |
ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
|
|
RS61010B1
(sr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3
|
|
WO2016085832A1
(en)
|
2014-11-24 |
2016-06-02 |
Albert Einstein College Of Medicine, Inc. |
Peptides for blocking il1rap protein-protein interaction and uses thereof for treatment of disease
|
|
JP6519913B2
(ja)
|
2015-02-05 |
2019-05-29 |
国立大学法人名古屋大学 |
ＩｇＥ結合性エピトープペプチドの利用
|
|
US9504694B2
(en)
|
2015-03-19 |
2016-11-29 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
|
TWI735433B
(zh)
|
2015-03-27 |
2021-08-11 |
美商再生元醫藥公司 |
偵測生物污染物之組成物及方法
|
|
MX387295B
(es)
|
2015-03-31 |
2025-03-18 |
Medimmune Ltd |
Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
|
|
WO2016179319A1
(en)
|
2015-05-04 |
2016-11-10 |
Cellerant Therapeutics, Inc. |
Chimeric antigen receptors with ctla4 signal transduction domains
|
|
KR20180003597A
(ko)
|
2015-05-08 |
2018-01-09 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
코르티스타틴 유도체로의 치료를 위한 환자의 표적화된 선택
|
|
CN108026172B
(zh)
|
2015-06-26 |
2022-04-29 |
赛诺菲生物技术公司 |
单克隆抗il-1racp抗体
|
|
WO2017011803A1
(en)
|
2015-07-16 |
2017-01-19 |
Cellerant Therapeutics, Inc. |
Cysteine-substituted immunoglobulins
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究（慕尼黑）公司 |
Ｃｄ７０及ｃｄ３抗體構築體
|
|
TW202440903A
(zh)
|
2015-08-04 |
2024-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法（一）
|
|
JP6858182B2
(ja)
|
2015-10-06 |
2021-04-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用
|
|
BR112018008908A2
(pt)
|
2015-11-02 |
2018-11-27 |
Janssen Pharmaceutica Nv |
anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
|
|
WO2017091615A1
(en)
|
2015-11-24 |
2017-06-01 |
Cellerant Therapeutics, Inc. |
Humanized anti-cll-1 antibodies
|
|
EP3394038A4
(en)
|
2015-12-23 |
2019-08-21 |
President and Fellows of Harvard College |
TARGETED SELECTION OF PATIENTS FOR TREATMENT WITH SPECIFIC CORTISTATINE DERIVATIVES
|
|
SG11201808693WA
(en)
|
2016-04-27 |
2018-11-29 |
Pfizer |
Anti-il-33 antibodies, compositions, methods and uses thereof
|
|
EP3241845A1
(en)
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Humanized anti-il-1r3 antibodies
|
|
CN106831998B
(zh)
|
2016-06-22 |
2020-09-15 |
徐州医科大学 |
一种人il1rap特异性car及其应用
|
|
JP6848241B2
(ja)
|
2016-07-25 |
2021-03-24 |
東ソー株式会社 |
Ｆｃ結合性タンパク質を用いたＩｇＧ１の精製方法
|
|
US20190225682A1
(en)
|
2016-09-02 |
2019-07-25 |
180 Therapeutics Lp |
Method of treating localized fibrotic disorders using an il-33/tnf bispecific antibody
|
|
WO2018053552A2
(en)
|
2016-09-19 |
2018-03-22 |
Cellerant Therapeutics, Inc. |
Isoquinolidinobenzodiazepines
|
|
CN110049780A
(zh)
|
2016-10-10 |
2019-07-23 |
塞勒兰特治疗公司 |
异喹啉并苯并二氮杂卓(iqb)-1(氯甲基)-2,3-二氢-1h-苯并[e]吲哚(cbi)二聚体
|
|
US10222376B2
(en)
|
2016-11-03 |
2019-03-05 |
The Charlotte-Mecklenburg Hospital Authority |
Methods and compositions for identifying leukemic stem cells
|
|
TWI784988B
(zh)
|
2016-12-01 |
2022-12-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
|
US20200315540A1
(en)
|
2016-12-14 |
2020-10-08 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
|
WO2018112425A1
(en)
|
2016-12-15 |
2018-06-21 |
Progenity Inc. |
Ingestible device and associated methods
|
|
CN116715775A
(zh)
|
2017-02-10 |
2023-09-08 |
豪夫迈·罗氏有限公司 |
抗类胰蛋白酶抗体、其组合物及其用途
|
|
MX2019012171A
(es)
|
2017-04-13 |
2019-11-25 |
Regeneron Pharma |
Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
|
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
|
KR102116178B1
(ko)
|
2017-05-10 |
2020-05-27 |
서울대학교산학협력단 |
간암 고위험군의 간암 발병 모니터링 또는 진단용 바이오마커 및 그 용도
|
|
KR20200014379A
(ko)
|
2017-06-05 |
2020-02-10 |
얀센 바이오테크 인코포레이티드 |
비대칭 ch2-ch3 영역 돌연변이를 갖는 조작된 다중특이성 항체 및 다른 다량체 단백질
|
|
WO2018231827A1
(en)
|
2017-06-12 |
2018-12-20 |
Bluefin Biomedicine, Inc. |
Anti-il1rap antibodies and antibody drug conjugates
|
|
KR20210084695A
(ko)
|
2017-07-06 |
2021-07-07 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
|
WO2019024979A1
(en)
|
2017-07-31 |
2019-02-07 |
Institute For Research In Biomedicine |
FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
|
|
US11370842B2
(en)
|
2017-08-01 |
2022-06-28 |
City Of Hope |
Anti-IL1RAP antibodies
|
|
WO2019060869A1
(en)
|
2017-09-25 |
2019-03-28 |
Discitisdx, Inc. |
METHODS FOR TREATING DEGENERATIVE DISC DISEASE AND CHRONIC LOMBALGIA
|
|
CA3082611A1
(en)
|
2017-11-17 |
2019-05-23 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for alleviating cytokine release syndrome
|
|
EP3489259A1
(en)
|
2017-11-23 |
2019-05-29 |
Etablissement Français du Sang |
Anti-il-1rap-car-t cells and their use
|
|
GB201720077D0
(en)
|
2017-12-01 |
2018-01-17 |
Univ Oxford Innovation Ltd |
Leukaemic stem cell
|
|
GB201800649D0
(en)
|
2018-01-16 |
2018-02-28 |
Argenx Bvba |
CD70 Combination Therapy
|
|
KR20220098056A
(ko)
|
2018-02-09 |
2022-07-08 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
GB201802307D0
(en)
|
2018-02-13 |
2018-03-28 |
Vib Vzw |
CD36 antagonists for use in melanoma treatment
|
|
US20210008047A1
(en)
|
2018-02-13 |
2021-01-14 |
Vib Vzw |
Targeting minimal residual disease in cancer with rxr antagonists
|
|
BR112020023508A2
(pt)
|
2018-05-24 |
2021-03-30 |
Janssen Biotech, Inc. |
Anticorpos anti-cd3 e usos dos mesmos
|
|
JP7428661B2
(ja)
|
2018-05-30 |
2024-02-06 |
中外製薬株式会社 |
Ｉｌ－１ｒ１結合ドメインおよび運搬部分を含むポリペプチド
|
|
KR20190140756A
(ko)
|
2018-06-12 |
2019-12-20 |
주식회사 노보셀바이오 |
자연 살상 세포에 결합하는 이중특이적 항체 및 이의 용도
|